Scopolamine is a medication traditionally used for motion sickness that shows rapid antidepressant effects within hours. It operates by blocking muscarinic acetylcholine receptors, diverging from conventional antidepressants which focus on serotonin pathways. Research indicates a response rate of 60-80% in treatment-resistant depression cases. Depression's prevalence impacts over 280 million people globally, with many failing to respond to standard treatments. The discovery of scopolamine's benefits represents a significant advancement in understanding and treating depression.
Scopolamine works by blocking muscarinic receptors, not serotonin pathways like conventional antidepressants.
Depression affects more than 280 million people worldwide, and approximately one-third of patients with major depressive disorder fail to respond to conventional antidepressants.
Scopolamine shows rapid antidepressant effects within hours, unlike traditional medicines that take weeks.
This treatment has a 60-80% response rate in treatment-resistant depression across multiple clinical trials.
Collection
[
|
...
]